Castle Biosciences, Inc.CSTLNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank81
5Y CAGR+14.5%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+14.5%/yr
Long-term compound
Percentile
P81
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 43.75% |
| Q3 2025 | -60.06% |
| Q2 2025 | 84.78% |
| Q1 2025 | -789.58% |
| Q4 2024 | -20.26% |
| Q3 2024 | 1.34% |
| Q2 2024 | 191.61% |
| Q1 2024 | 3.31% |
| Q4 2023 | 41.31% |
| Q3 2023 | 54.44% |
| Q2 2023 | 32.88% |
| Q1 2023 | -38.06% |
| Q4 2022 | -6.02% |
| Q3 2022 | 11.63% |
| Q2 2022 | 0.60% |
| Q1 2022 | -61.60% |
| Q4 2021 | -28.42% |
| Q3 2021 | -34.10% |
| Q2 2021 | -105.65% |
| Q1 2021 | -41.29% |
| Q4 2020 | 22.28% |
| Q3 2020 | -504.81% |
| Q2 2020 | -162.26% |
| Q1 2020 | -60.35% |
| Q4 2019 | -41.01% |
| Q3 2019 | 628.94% |
| Q2 2019 | 289.03% |
| Q1 2019 | -106.74% |
| Q4 2018 | 267.18% |
| Q3 2018 | -6.95% |
| Q2 2018 | 13.57% |
| Q1 2018 | 0.00% |